1 Universal digital high resolution melt analysis for the diagnosis of bacteremia 2 April Aralar,<sup>a</sup> Tyler Goshia,<sup>a</sup> Nanda Ramchandar,<sup>b,c</sup> Shelley M. Lawrence,<sup>d</sup> Aparajita Karmakar,<sup>e</sup> 3 Ankit Sharma,<sup>e</sup> Mridu Sinha,<sup>e</sup> David T. Pride,<sup>f</sup> Peiting Kuo,<sup>f</sup> Khrissa Lecrone,<sup>f</sup> Megan Chiu,<sup>f</sup> 4 Karen Mestan,<sup>g</sup> Eniko Sajti,<sup>g</sup> Michelle Vanderpool,<sup>h</sup> Sarah Lazar,<sup>g</sup> Melanie Crabtree,<sup>g</sup> Yordanos 5 Tesfai,<sup>9</sup> Stephanie I.Fralev<sup>a\*</sup># 6 7 8 <sup>a</sup>Department of Bioengineering, University of California, San Diego, La Jolla, CA, USA 9 <sup>b</sup>Department of Pediatrics, Naval Medical Center San Diego, San Diego, CA, USA <sup>c</sup>Department of Pediatrics, Division of Infectious Diseases, University of California, San Diego, 10 La Jolla, CA, USA 11 12 <sup>d</sup>Department of Pediatrics, Division of Neonatology, The University of Utah, Salt Lake City, UT, 13 USA 14 <sup>e</sup>MelioLabs, Inc, Santa Clara, CA, USA 15 <sup>t</sup>Department of Pathology, University of California, San Diego, La Jolla, CA, USA 16 <sup>g</sup>Department of Pediatrics, Division of Neonatology, University of California, San Diego, La Jolla, 17 CA. USA 18 <sup>h</sup>Department of Pathology and Laboratory Medicine, Rady Children's Hospital – San Diego, San 19 Diego, San Diego, CA, USA 20 21 Running Head: Pathogen ID and quantification in blood using UdHRM

22 #Address correspondence to Stephanie I. Fraley, sifraley@eng.ucsd.edu.

23 \*Present address: Stephanie Fraley, University of California, San Diego, 9500 Gilman Drive,

24 MC0435, La Jolla, CA 92093, USA

25

### 26 Universal digital high resolution melt analysis for the diagnosis of bacteremia

27

April Aralar, Tyler Goshia, Nanda Ramchandar, Shelley M. Lawrence, Aparajita Karmakar, Ankit
Sharma, Mridu Sinha, David Pride, Peiting Kuo, Khrissa Lecrone, Megan Chiu, Karen Mestan,
Eniko Sajti, Michelle Vanderpool, Sarah Lazar, Melanie Crabtree, Yordanos Tesfai, Stephanie I.

- 31 Fraley
- 32

#### 33 ABSTRACT

34 Fast and accurate diagnosis of bloodstream infection is necessary to inform treatment decisions 35 for septic patients, who face hourly increases in mortality risk. Blood culture remains the gold 36 standard test but typically requires ~15 hours to detect the presence of a pathogen. Here, we 37 assess the potential for universal digital high-resolution melt (U-dHRM) analysis to accomplish 38 faster broad-based bacterial detection, load quantification, and species-level identification 39 directly from whole blood. Analytical validation studies demonstrated strong agreement between 40 U-dHRM load measurement and quantitative blood culture, indicating that U-dHRM detection is 41 highly specific to intact organisms. In a pilot clinical study of 21 whole blood samples from 42 pediatric patients undergoing simultaneous blood culture testing, U-dHRM achieved 100% 43 concordance when compared with blood culture and 90.5% concordance when compared with 44 clinical adjudication. Moreover, U-dHRM identified the causative pathogen to the species level 45 in all cases where the organism was represented in the melt curve database. These results 46 were achieved with a 1 mL sample input and sample-to-answer time of 6 hrs. Overall, this pilot 47 study suggests that U-dHRM may be a promising method to address the challenges of quickly 48 and accurately diagnosing a bloodstream infection.

49

### 50 INTRODUCTION

Sepsis is among the most common causes of death in hospitalized patients. One out of every 51 52 five deaths worldwide are estimated to be due to sepsis-related complications, with 41% occurring in children.<sup>1</sup> Early detection of the infectious cause is critical for sepsis survival, as 53 every hour the infection goes undiagnosed or inaccurately treated mortality risk rises by 4%.<sup>2-4</sup> 54 55 However, rapid diagnosis of bloodstream infection (BSI) has proven to be extremely challenging.<sup>5</sup> Blood culture remains the gold-standard test despite significant false positive and 56 57 negative error rates and slow time-to-result, ranging from ~15 hours to 5 days.<sup>6-12</sup> 58 Consequently, treatments remain un-targeted, contributing to antimicrobial resistance and 59 opportunistic infections.

60

Nucleic acid amplification tests (NAATs) have been heralded as the solution to this challenge. 61 However, NAATs are associated with higher rates of bacterial DNA detection compared to 62 63 bacterial growth in blood culture. They also detect bacterial DNA in the blood of healthy 64 patients, which has constrained their impact and widespread adoption by the medical community. For example, multiplexed PCR detection of microbial DNA in blood suffers from 65 false positives that overestimate the concentration of pathogens in clinical samples.<sup>13–15</sup> False 66 negatives also arise from low concentrations of pathogens and subsampling errors.<sup>16-18</sup> 67 Likewise, the off-target interaction of primers with human DNA, which vastly outnumbers 68 69 bacterial DNA in blood, can contribute to both false-positive and false-negative test results.<sup>19-26</sup>

These limitations extend to commercialized PCR-based strategies such as Iridica, Septifast, and
 SeptiTest.<sup>7,12</sup>

72

73 Sequencing technologies have recently emerged in an attempt to address some of the limitations of more targeted NAATs, but have had limited utility in actual clinical settings.<sup>27-32</sup> 74 Their primary advantage is broad-based detection, but they detect a wide variety of background 75 DNA of no clinical significance, making the interpretation of their results difficult. <sup>19,29,30,33</sup> Recent 76 77 studies show that they can be helpful in cases of rare pathogens, but add little to no clinical value otherwise.<sup>27,28,34,35</sup> Additionally, sequencing results are not quantitative, a feature which 78 may help in distinguishing symptomatic infections from colonization or contamination.<sup>28,32</sup> They 79 80 are also limited to the send-out format of testing due to their high complexity, batch processing, large format equipment, and expertise required to run and analyze the data.<sup>36–40</sup> Therefore, they 81 cannot be implemented in typical hospital labs. Most importantly, multiple studies have shown 82 that sequencing take even longer than the average blood culture to report an answer.<sup>27,28</sup> 83

84

85 Towards advancing the field of BSI diagnostics, we have developed an approach called universal digital high-resolution melt analysis (U-dHRM)<sup>41-43</sup>, which conducts universal bacterial 86 87 amplification in digital PCR (dPCR) followed by digital high resolution melt (dHRM) analysis of DNA amplicons to identify and quantify organisms by their sequence-specific melt curve 88 fingerprints with machine learning (ML)<sup>44,45</sup>. This approach distinguishes itself from standard 89 NAAT HRM-based diagnostics by its potential for unbiased broad-based pathogen identification. 90 absolute quantification of organism(s) load (even in polymicrobial samples), and capability to 91 92 expand organism identification without assay redesign. To achieve breadth and specificity, U-93 dHRM relies on probe-free melting of long amplicons covering extensive sequence 94 hypervariability in barcoding genomic regions and uses all the temperature points of multimodal melt curve signatures in a Tm-independent manner to identify organisms.<sup>44,45</sup> Absolute 95 quantification and single genome analysis is achieved by digital partitioning of genomes into 96 separate reactions for individual melt analysis and quantification.<sup>46,47</sup> Previous work established 97 proof-of-principal for these functions.44,45 98

99

100 Here, we advanced U-dHRM for analytical and clinical performance testing directly from whole 101 blood matrix. Sample preparation techniques that enrich for intact pathogens were integrated 102 upstream of U-dHRM and universal bacterial primers were optimized to limit off-target 103 interactions with human DNA that carries over from blood during extraction. To power reliable 104 ML classification on clinical samples, thousands of digital training curves were generated for 11 105 clinically relevant pathogens spiked into whole blood. The performance of this advanced U-106 dHRM workflow was tested on 21 patient samples, where it achieved accurate and fast 107 organism identification and quantification directly from whole blood in 6 hr.

108

### 109 METHODS

### 110 Whole Blood Sample Preparation

111 The Molysis Complete 5 kit (Molzym GmbH& Co. KG, Bremen, Germany) was selected for 112 whole blood sample preparation prior to U-dHRM analysis. Molysis is designed to deplete host

113 DNA and enrich for microbial DNA from intact cells. The residual concentration of human DNA

following Molysis processing of 1mL whole blood was quantified by dPCR with  $\beta$ -actin gene primers (see PCR Master Mixes section for details) to be  $4.67*10^2-5.67*10^3$  copies/µL in the sample extraction elute (Supplementary Fig. 1). This indicated that human DNA can carryover into a significant proportion of the available partitions of the dPCR chip during U-dHRM analysis and prompted the screening of universal bacterial 16S primers for off-target interactions with human DNA, given their known homology<sup>19</sup>.

120

#### 121 Primer Selection and Internal Amplification Control

122 Universal primer sequences were identified through literature review and tested in BLAST for 123 alignment to the human genome. Apart from V6R which was used as a control sequence, 124 primer sequences were selected for screening if there was <85% guery coverage. As an 125 additional strategy for promoting the detection of intact microbes, primer pairs were required to produce a long amplicon (>600 bp) capable of discriminating against degraded DNA.48-50. 126 Amplicons were also required to include the important hypervariable regions (V4 and V6) for 127 differentiation of the greatest number of bacterial species.<sup>51</sup> Supplementary Table 1 lists the 128 129 primer pairs selected for screening and their characteristics.

130

131 To assess off-target interactions, human genomic DNA was extracted from healthy cord blood 132 using the Wizard Genomic DNA Purification Kit (Promega, Madison, WI) and spiked into qPCR 133 reactions at post-Molysis concentrations (approximately 1 ng/uL DNA based on 134 spectrophotometer reading) with 16S primers. Results were confirmed in dPCR. In gPCR, 135 several primer pairs amplified earlier than others and produced melt curves that were consistent 136 within a primer pair (Supplementary Fig. 2A), suggesting off-target yet reliable interactions. 137 V1F/V9R showed no off-target amplification in qPCR, indicated by the absence of both a cycle 138 threshold (Ct) curve and a melt curve (Supplementary Fig. 2A). Similar results were found in 139 dPCR. Supplementary Fig. 2B shows the amplified partitions from dPCR and the resultant 140 dHRM melt curves for each primer pair. Taller and more consistent melt curves indicate 141 stronger interactions between the primers and the human DNA. The V1F/V9R primer pair 142 produced the smallest number of off-target curves, and they were noisy, short, and inconsistent, 143 indicating weak and rare interactions (Supplementary Fig. 2C, green box). The number of off-144 target melt curves counted for each primer pair is shown in Supplementary Fig. 2C. Additional 145 testing with no template control (PCR water) and bacterial DNA (E. coli) further demonstrated 146 that V1F/V9R has low off-target and high on-target amplification (Supplemental Fig. 3).

147

148 V1F/V9R was then confirmed in qPCR to amplify bacterial qDNA extracted from different 149 representing common bloodborne pathogens in the pediatric population species (Supplementary Table 2)<sup>52</sup>. Supplementary Fig. 4A shows the alignment of the primer pair to the 150 151 16S gene of each organism, and Supplementary Fig. 4B shows singular, consistent melting 152 curves for each of the bacterial amplicons, indicating that amplification was specific. With the 153 addition of post-Molysis levels of human DNA (Supplementary Fig. 4C), similar melt curves 154 were produced. Their amplitude was slightly lower, suggesting that slight dPCR amplification 155 inhibition occurs in the presence of residual human DNA. These qPCR results verified that 156 V1F/V9R is capable of broad-based bacterial DNA amplification and exclusion of human DNA 157 amplification at concentrations expected following host DNA depletion by Molysis.

158

159 Finally, the behavior of the V1F/V9R primers were evaluated in dPCR for contrived bacteremic 160 blood samples pre-processed by Molysis. For these experiments, we also included our previously developed internal amplification control (IAC) that improves quantification in dPCR <sup>53</sup>. 161 162 The IAC generates an amplicon that melts at a lower temperature than bacterial amplicons in 163 dHRM. We verified that the IAC assay components do not interact with V1F/V9R by generating 164 blood matrix spike (MS) samples with E. coli or no template control (NTC) samples with sterile 165 PBS, processing them with Molysis, and analyzing them by U-dHRM. Supplementary Fig. 5A 166 shows that for the E. coli spiked sample, both the IAC and E. coli melt curves or the IAC melt 167 curves alone or no melt curves are produced per partition at expected levels. Supplementary 168 Fig. 5B shows that the NTC sample only generated melt curves for the IAC or were negative for 169 amplification. IAC negative reactions are excluded during concentration calculations to improve quantification.53 170

171

### 172 PCR Master Mixes

173 All PCRs were performed using a 15-µL total reaction volume. All PCR reactions with the 174 exception of those conducted for identity verification by sequencing and human DNA 175 quantification experiments consisted of 1x Phusion GC PCR buffer (Thermo Scientific, 176 Waltham, MA), 2x ROX dye (Bio-Rad, Hercules, CA), 0.02 µM IAC primers, 0.1 µM IAC 177 template, 0.1 µM each bacterial primer (IDT), 2.5× EvaGreen (Biotium, Fremont, CA), 0.2 □mM 178 deoxynucleoside triphosphate (dNTP) (Invitrogen, Carlsbad, CA), 0.02 U/µL Phusion 179 polymerase (New England Biolabs, Ipswich, MA), 3 µL of genomic DNA dilution, and ultrapure 180 water (Quality Biological, Gaithersburg, MD). Identification verification and human DNA 181 quantification experiments were performed in qPCR without the IAC template and bacterial 182 primers in the master mix.

183

184 The following  $\beta$ -actin primer sequences were used <sup>54</sup>: Forward 5'-185 CGGCCTTGGAGTGTGTATTAAGTA-3', Reverse 5'-TGCAAAGAACACGGCTAAGTGT-3'.

186

The internal control template and primer were used at the concentrations determined previously
 to promote amplification in a maximum number of wells without outcompeting the amplification
 of low-level bacterial targets.<sup>53</sup> The IAC template sequence is as follows <sup>53</sup>: 5' CCATAGACGTAGCAACGATCGTGAGGTAGTAGATTGTATAGTTGATGCAAGGACTA

191 TCCACTCAC-3'. The IAC was linearly amplified using only a forward primer 5'-192 CGATCGTTGCTACGTCTATGG-3'.

193

## 194 PCR and HRM Cycling Conditions

The qPCR experiments were performed on a Bio-Rad CFX 96 (Bio-Rad, Hercules, CA). UdHRM thermocycling was performed on a ProFlex 2 x Flat Block Thermal Cycler (Applied Biosystems, Waltham, MA). For β-actin amplification, thermocycling for both dPCR and qPCR proceeded as follows: hold at 98°C for 30 s, followed by 70 cycles of 98°C for 10 s, 65.2°C for 30 s, and 72°C for 45 s. For all other reactions, thermocycling for both dPCR and qPCR proceeded as follows: hold at 98°C for 30 s, followed by 70 cycles of 98°C for 10 s, 62°C for 30 s, and 72°C for 45 s. qPCR amplification was followed by a melt cycle of 95°C for 15 s, 45°C for

60 s, and 96°C for 5 s). dPCR amplification was followed by a melt cycle on a Melio MeltRead<sup>™</sup>
 Platform dHRM heating device and simultaneously imaged on a custom Olympus microscope
 setup as previously described.<sup>46,55</sup>

205

### 206 Generation of Spiked and Control Blood Samples

207 Eleven bacterial species were obtained from either the American Type Culture Collection 208 (ATCC), from the Pride Lab at the University of California at San Diego (UCSD), or from the 209 Microbiology Lab at Rady Children's Hospital, San Diego (RCHSD). The bacteria were cultured 210 in liquid media according to ATCC guidelines. To verify organism identities, genomic DNA from 211 each species was extracted using the Wizard Genomic DNA purification kit (Promega 212 Corporation, Madison, WI). The DNA concentration was measured by biospectrophotometer 213 and diluted in one 10-fold serial dilution before undergoing qPCR amplification with 16S primers. 214 DNA products were then sent for Sanger sequencing.

215

#### 216 Melt Curve Database

217 To generate the melt curve database for these organisms, each bacterial species was cultured 218 in liquid culture in the ATCC recommended broth overnight, and 1 mL of freshly prepared 219 bacterial suspension was centrifuged and resuspended in sterile PBS. The turbidity was 220 adjusted to  $OD_{600} = 1$ , measured on an biospectrophotometer. Each species of bacteria was 221 spiked into 2 mL of healthy human cord blood at a ratio of 1:10 bacterial suspension to blood. 222 The sample was then split, with 1 mL cultured on agar plates to verify bacterial growth while the 223 other mL went through the Molysis Complete 5 Microbial DNA isolation protocol (Molzym, 224 Bremen, Germany). DNA products were amplified by gPCR and identity verified by Sanger 225 sequencing. Following identity verification, DNA samples were diluted in one ten-fold dilution 226 and analyzed by U-dHRM as described above. This spiking and extraction process was 227 performed twice for each organism to encompass 2 biological replicates, and technical 228 replicates were created from each extraction. Each organism had a total of 8 chips analyzed to 229 create the bacterial melt curve database. The melt curves from each organism were combined 230 and clustered according to the ML algorithm described below and in the supplemental materials. 231 Representative melt curves were generated by the ML algorithm, aligned by their highest peaks, 232 and averaged (see Supplementary Methods).

233

#### 234 Analytical Validation Studies

235 Mock samples for analytical validation studies were generated in a similar manner. Briefly, E. 236 coli was cultured in LB broth overnight, and 1 mL of freshly prepared bacterial suspension was 237 centrifuged and resuspended in sterile PBS. The turbidity was adjusted to  $OD_{600} = 0.5$ , 238 measured on an Eppendorf Biospectrophotometer. Six 10-fold serial dilutions were conducted to 239 achieve concentrations down to 0.1 CFU/mL. Bacteria from each concentration were spiked into 240 2 mL of healthy human cord blood to achieve the final concentrations of 10k, 1k, 100, 10, 1 and 241 0.1 bacterial cells/mL of blood. Concurrently, an NTC sample was prepared by adding sterile 242 PBS to the blood at the same volume as the bacterial spike. One mL of each sample was split 243 off and underwent Molysis Complete 5 Microbial DNA isolation and quantification by U-dHRM. 244 The other mL of blood underwent quantitative blood culture (QBC) by plating 100 µL of blood on 245 10 agar plates to verify bacterial growth and quantity CFU.

### 246

Elution blank samples were also prepared to assess the level of background in the reagents and disposables. These were generated following Molzym's standard negative control test procedure, which consists of processing 1mL of SU buffer (included in the Molysis Complete 5 Kit) through the standard Molysis microbial DNA isolation protocol. Three elution blanks were processed and each was analyzed by U-dHRM across 6 chips following the same procedure as was used for the spiked matrix samples.

253

## 254 Clinical Sample Testing Procedure

For all scavenged whole blood samples, 1 mL of blood was processed by the Molysis Complete 5 kit (Molzym, Bremen, Germany). Immediately afterwards, the DNA elute was processed concurrently by qPCR detection and U-dHRM quantification using the PCR master mix formulas for bacterial amplification and the PCR protocols described above. Three reactions were run for qPCR testing and three reactions were performed in U-dHRM for each sample. For each method, 9 µL total was sampled out of the 100 µL elute.

261

## 262 Clinical Samples Scavenging Protocol and Inclusion/Exclusion Criteria

263 The study protocol was reviewed and approved by the Institutional Review Board (IRB) and 264 Ethics Committee (No. 191392) of the University of California, San Diego (UCSD) and Rady 265 Children's Hospital in San Diego (RCHSD). A materials transfer agreement (MTA) between 266 RCH and UCSD was executed to enable sample transfer. The age ranges of samples used for 267 this study are shown in Supplementary Table 3. In total, 21 samples were scavenged that met 268 inclusion/exclusion criteria as defined below. Among both positive and negative scavenged CBC 269 samples, 42.9% of the samples were female and 57.1% were male. Racially, 19% of the 270 samples were Asian, 9.5% were black or African American, 28.6% were Hispanic/Latino/Latinx, 271 and 42.9% were White.

- 272
- 273 Positives

274 Remnant CBC samples were scavenged from the RCHSD hematology lab. CBCs were tagged 275 for scavenging if a blood culture result from the same patient was flagged positive in RCHSD's 276 clinical microbiology lab. Once a CBC was tagged for collection, an honest broker de-identified 277 the sample and logged sample characteristics. The sample was then transferred to UCSD and 278 processed by U-dHRM the same day. Scavenged CBCs were excluded if they did not meet the 279 following criteria:

- (1) The CBC and positive blood culture sample were drawn at the same time (within 1 minute).
- 282 (2) No antibiotics were administered within the same hospital visit prior to collection.
- 283 (3) At least one milliliter was scavenged.
- 284

Seven CBC samples met these criteria during the collection timeframe. It is important to note that these blood samples were first held at room temperature prior to CBC processing and were then transferred to refrigerated storage at  $4\Box$  in the clinical microbiology lab, where there was a minimum 24-hour hold time until the sample was released to be scavenged. Most pathogenic bacteria do not grow under such conditions<sup>56,57</sup>, so it is unlikely that this hold time would

substantially increase the bacterial load that U-dHRM quantifies. However, it is possible thatsome bacterial cell death occurs during this time.

292

293 To assess this possibility, we conducted mock sample aging studies. Briefly, E. coli was 294 cultured in LB broth overnight, and 1 mL of freshly prepared bacterial suspension was 295 centrifuged and resuspended in sterile PBS. The turbidity was adjusted to  $OD_{600} = 0.5$ , 296 measured on a biospectrophotometer. Ten-fold serial dilutions were conducted and bacteria 297 from two concentrations were spiked into 2 mL of healthy human cord blood to achieve the final 298 concentrations of 10,000 and 1,000 bacterial cells/mL of blood. The 2mL sample was then split: 299 1mL was immediately processed and 1mL was stored at 4°C for 24 hours before being processed by the 300 Molysis DNA extraction method and subsequent U-dHRM analysis. The measured concentrations of 301 bacteria were compared before and after refrigeration. This experiment was conducted 3 times. A 302 slight but insignificant drop in was detected after refrigeration at both spike concentrations, as 303 shown in Supplemental Fig. 6. While this is not an exhaustive sample aging study, it suggests 304 that the number of organisms detected in the CBC samples may not be strongly impacted by 305 refrigerated storage time. It is important to note that our molecular detection approach only 306 requires organisms to be intact such that their gDNA is protected from degradation during 307 Molysis sample preparation. Viability or culturability is not a requirement for detection by U-308 dHRM.

309

## 310 Negatives

311 Within the same IRB protocol described above, remnant CBCs matched to blood culture negative samples were scavenged from RCHSD. CBCs were tagged for scavenging if a blood 312 313 culture result from the same patient resulted as negative in RCHSD's clinical microbiology lab. 314 Once a CBC was tagged for collection, an honest broker de-identified the sample and logged 315 sample characteristics. The sample was then transferred to UCSD and processed by U-dHRM 316 the same day. During the collection timeframe, 14 negative samples were scavenged. The 317 majority of these were found to have had antibiotic exposure at the time of blood draw. 318 Therefore, we amended our exclusion criteria for negatives to ensure sufficient sample size. 319 Scavenged negative CBCs were excluded if they did not meet the following criteria:

- 320 (1) The CBC and blood culture negative sample were drawn at the same time (within 1321 minute)
  - 322 323

(2) At least one milliliter was scavenged

## 324 U-dHRM Data Curation, Preprocessing, and Melt Curve Classification

325 A detailed description of the melt curve analysis methods, including the Python packages used, 326 can be found in the Supplementary Methods. Briefly, we employed an optimized image 327 processing, melt curve preprocessing, and machine learning (ML) pipeline for extracting, 328 analyzing, and classifying curves. Fluorescence data extraction from dPCR chips imaged during the dHRM heating process was performed using the protocol detailed in <sup>53</sup>, and with appropriate 329 330 temperature-to-time mapping, each resulting raw melt curve was converted to a time series (TS). These fluorescence TS were converted to derivative TS and filtered using several peak-331 332 based criteria. Finally, TS smoothing, cropping, and normalizations were performed to 333 preprocess the data into a format appropriate for the downstream ML algorithms.

#### 334

335 A two-step classification process was developed for derivative TS classification. Since the melt 336 curves have significant variations and noise within and between chips, K-means clustering was 337 used as a first step to extract the key clusters of variations along with respective cluster centers, 338 which are more robust compressed signals. In the second step, a k-Nearest Neighbour (kNN) 339 classifier was used to classify a test curve by comparing its distance from the cluster centers 340 from the first step. Both the Dynamic Time Warping (DTW) distance, which can take y-axis 341 scaling or x-axis shifting variations into account, and the Euclidean distance are measured, and 342 compared for agreement. If the closest organism call matches by both DTW and Euclidean 343 distance, then the test cluster is confidently called as that respective organism. If the DTW and 344 Euclidean calls do not match, the cluster is considered "low confidence". Low confidence called 345 clusters can stem from noisy signals, or from novel curves that may not be represented in the 346 database yet.

347

Classification accuracy was assessed for the database of organism melt curves by dividing the database curves into training and test sets and conducting cross validation experiments. For patient samples, the extracted TS are first clustered using DTW-based K-means, and the obtained cluster centers, or representatives, are classified using the kNN-based classifier that was built using the database curves.

353

#### 354 Statistical Analysis

All statistical analyses were performed in Graphpad Prism 5 (Dotmatics, Boston, MA). A oneway analysis of variance (ANOVA) was conducted on the analyzed testing groups (extraction blanks, culture negative matched CBCs, and culture positive matched CBCs) with a Bonferroni posttest to compare all pairs of columns.

359 360

## 361 **RESULTS**

362

### 363 Digital Melt Curve Database Generation and Classification in Spiked Whole Blood Matrix

364 Whole blood matrix spike (MS) samples were generated for 11 organisms (Supplementary 365 Table 2), representing some of the most common causes of BSI among pediatric patients<sup>52</sup>, and 366 analyzed by U-dHRM with primers targeting the V1-V9 regions of the bacterial 16S rRNA gene. 367 Fig. 1A shows representative melt curves for each organism, highlighting the clear visual 368 differences between the V1-V9 melt curve fingerprints. Raw curves can be seen in 369 Supplementary Fig. 7. Coagulase-negative staphylococci (CoNS) species (S. hominis and S. 370 epidermidis) were combined since their treatment does not differ and they are often considered 371 contaminants. A ML algorithm, which relies on agreement between two classification strategies 372 (see Methods section), demonstrated an average of 97% classification accuracy on this dataset, 373 which included >146,000 training curves (Supplementary Table 4). The number of curves 374 (support) that were used in this analysis for each organism is also detailed in Supplementary 375 Table 4. A confusion matrix resulting from leave one out cross validation (LOOCV) experiments 376 is shown in Fig. 1B. Consistent with the classification accuracy score of 97%, the confusion 377 matrix shows that the vast majority of digital melt curves are classified as the correct organism.

378 Misclassifications occurred rarely, mostly in the *Staphylococcus* genus. These results 379 demonstrate the ability of V1-V9 U-dHRM combined with ML to reliably and automatically 380 differentiate organisms in spiked blood samples.

381

### 382 Analytical Validation

383 As a preliminary assessment of quantitative power of U-dHRM, six concentrations of E. coli 384 were spiked into a healthy human blood matrix and compared to a no template control (PBS) 385 spiked blood samples. These samples were split in half and underwent paired testing by U-386 dHRM analysis and quantitative blood culture (QBC) (Fig. 2A). U-dHRM quantification showed 387 excellent agreement with QBC in the concentration range of 10,000-10 CFU/mL, with a Pearson 388 r value of 0.9988 and a p-value of 0.0012 (Fig. 2B). However, at concentrations below 10 389 CFU/mL, detection variability increased as a result of the extraction elute volume sampled by U-390 dHRM. From 1mL of blood, extraction elutes 100ul and U-dHRM sampled 9ul of this elute 391 across three chips (3ul each). This results in 1 curve detected per 3 chips equating to 11.1 392 CFU/mL, and limits quantification below this level. For this reason, when bacteria are spiked at 393 dilutions lower than 10 CFU/mL, U-dHRM quantifies bacteria at 0 CFU/mL (0 curves) or 10 394 CFU/mL (1 curve). However, for practical reasons, we continued with this format for this pilot 395 study. Extraction blank (EB) samples were tested according to the manufacturer recommended 396 negative control method, which showed a very low level of background originating from the 397 reagents and/or disposables used in the process (Fig. 2B). ML classification of these curves 398 against our database did not identify any matches to the database organisms.

### 400 Pilot Clinical Testing

401 Next, we conducted U-dHRM analysis on 21 whole blood samples from patients ranging in age 402 from infants to toddlers (Supplementary Table 3). These were remnants of complete blood 403 count (CBCs) that were drawn from pediatric patients undergoing blood culture for suspicion of 404 BSI. Only CBCs drawn at the same time from the same location as a blood culture draw were 405 included (see Methods section). Of these 21 samples, 14 were matched to negative cultures 406 and 7 were matched to positive cultures. Clinician adjudication of blood culture results was 407 performed by a practicing physician in the Department of Pediatrics, Division of Infectious 408 Diseases at Rady Children's Hospital. The clinician reviewed the charts for each patient and 409 each specific sample to determine if the blood culture results indicated a probable infection 410 when compared to patient inflammatory markers, final diagnosis, additional diagnostic tests, 411 success of prescribed treatment, and any other relevant clinical information. A summary of 412 blood culture results, clinical diagnostic details for each sample, and clinician adjudicated 413 diagnosis for blood culture positive samples is presented in Table 1.

414

399

The machine learning algorithm, which was trained to classify database curves from spiked blood samples (Fig. 1), was used to automatically classify melt curves detected in the patient samples. Melt curves were determined to be either a high or low confidence match to the database organisms, or unmatched. Algorithms for high confidence, low confidence, and unmatched calling are detailed in the Methods and Supplemental Methods sections.

420

### 421 **Results for CBC Negative Samples**

422 All of the 14 CBC samples matched to negative blood cultures were reported to be negative for 423 any organism curves by the ML algorithm.

424

# 425 Results for CBC Positive Samples

In positive CBC samples 1-5, ML curve classification identified high confidence matches to the same organisms identified by blood culture (Table 1). Representative melt curves detected by ML classification are shown in Fig. 3 A-I. In a few cases, additional organisms were detected by U-dHRM. In sample 3 where *S. enterica* was the primary pathogen detected by both BCID and U-dHRM (Fig. 3C), *S. maltophilia* was also detected at lower levels by U-dHRM (Fig. 3D). In sample 5, where *S. enterica* was detected by BCID and U-dHRM (Fig. 3F), *S. aureus* was also detected by U-dHRM (Fig. 3G).

433

CBC samples 6 and 7 had discordant BCID and U-dHRM organism identifications. In sample 6,
blood culture found gram positive rods (GPR) and post-culture ePlexID identified *Bacteroides*.
Clinical adjudication determined this to be a false positive (Table 1). U-dHRM detected CoNS
with high confidence (Fig. 3H).

438

In sample 7, blood culture found gram negative rods (GNR) and post-culture ePlexID identified *Enterobacter* non *cloacae*. However subsequent blood draws on this patient resulted in later detection of *Klebsiella* by BCID and clinician adjudication confirmed Klebsiella BSI (Table 1). UdHRM did not identify high confidence matches in this sample, but did identify low confidence matches to *K. pneumoniae* (Fig. 3I). Low confidence matches for all samples are shown with their closest database matches in Supplementary Figures 8-11.

445

Fig. 3J shows the bacterial load quantified by U-dHRM in each CBC sample for high confidence
matches. The time to result (TTR) for U-dHRM, 6hr, was substantially faster than BCID in all
cases (Table 1). U-dHRM ranged from 7.5hr to 2d 18hr faster than BCID TTR for positives.
Negatives are confirmed by BCID at 5d.

450

In summary, the overall concordance for the detection of bacteremia in whole blood samples was 21/21 (100%) from the perspective of blood culture as truth and 19/21 (90.5%) from the perspective of clinically adjudicated findings as truth. In the 5 samples determined to be true bacteremia by clinician adjudication, U-dHRM accurately identified the organism in 5/5, with 4 high confidence matches and 1 low confidence match.

456

# 457 **DISCUSSION**

458 U-dHRM with ML achieved accurate organism identification in spiked whole blood samples and 459 in clinical whole blood samples, suggesting that this approach can overcome a common pitfall of standard HRM where interference from biological substances in whole blood that co-extract with 460 DNA cause large Tm shifts.<sup>58</sup> U-dHRM overcomes this by generating thousands of example 461 462 curves for each organism, which are identified independently of Tm by curve shape matching 463 using ML. Interfering substances that carryover from blood can also impact the sensitivity and 464 quantitative power of standard PCR-based assays by reducing amplification efficiency. U-dHRM 465 achieved excellent quantitative agreement with QBC in the range of 10,000-10 CFU/mL in

spiked blood by relying on endpoint detection, which overcomes efficiency bias and enables
absolute quantification. Below 10 CFU/mL, U-dHRM was unable to accurately quantify because
only ~10% of each 1mL sample volume was tested. This limitation can be overcome by
analyzing more of the extracted sample volume, concentrating the elute, running more chips per
sample, increasing the number of digital partitions, or increasing the volume of digital partitions.
Nonetheless, some differences between blood culture and molecular detection approaches may
persist due to the presence of viable but non-culturable cells.<sup>59</sup>

473

In pilot clinical sample testing, U-dHRM demonstrated 14/14 (100%) agreement with culture negative samples. Given that universal bacterial primers form the basis of the assay, this result suggests that the testing process used was successful in limiting the detection of background and degraded DNA of no clinical significance. The sample preparation method used is specifically designed to bias detection towards DNA from intact/living bacteria cells by degrading cell-free DNA before microbe lysis. Also, the length of the V1-V9 amplicon, ~1400 bp, biases towards non-degraded DNA.

481

482 U-dHRM also demonstrated 7/7 (100%) agreement with blood culture positivity, although two of 483 these (samples 1 and 6) were determined by the adjudicating clinician to be false positive blood 484 cultures. For sample 1, both BCID and U-dHRM detected CoNS. However, the final diagnosis 485 was a urinary tract infection (UTI) caused by E. coli. The patient was not treated for an S. 486 epidermidis BSI, but was treated for the UTI and improved, leading the adjudicating clinician to 487 believe that the S. epidermidis was a contaminant. Since S. epidermidis/CoNS was detected by 488 both methods, this was likely a true live cell contaminant. For sample 6, BCID detected 489 Bacteroides while U-dHRM detected CoNS and two other curves that did not match any 490 organisms in our database. The final diagnosis was polymicrobial skin and soft tissue infection 491 (SSTI). In older children and adults, BCID of CoNS is usually considered to be a false positive 492 caused by contamination, but in neonates it can indicate true BSI<sup>60</sup>. In the future, the absolute 493 quantitative power of U-dHRM may be able to help to further refine these heuristics by defining 494 clinically relevant load ranges that differentiate true bacteremia in need of treatment from 495 common contamination levels for organisms that can be both pathogen and commensal.

496

497 The U-dHRM sample to answer time was 6hr for all samples, while BCID TTR ranged from 498 ~13.5hr to 3d for positive samples and up to 5d for negative samples. Interestingly, the positive 499 samples with the longest TTR by blood culture (samples 2 and 3, TTR ~2d and 3d respectively) 500 were determined to have some of the highest bacterial loads by U-dHRM. Both U-dHRM and BCID identified S. enterica, which is known to grow slowly in blood culture because it is an 501 intracellular pathogen that prefers to grow in macrophages.<sup>61</sup> Blood culture and bone marrow 502 culture are limited in their ability to recover this pathogen,<sup>62</sup> even in patients harboring loads of 503 1.01\*10<sup>3</sup> to 4.35\*10<sup>4</sup> copies/mL.<sup>63</sup> Clinical adjudication revealed that samples 2 and 3 originated 504 505 from the same patient but were taken on subsequent days. U-dHRM quantified the first blood 506 draw from this patient (sample 2) as having three times the concentration of S. enterica as the 507 second draw on the following day (sample 3). However, U-dHRM also detected S. maltophilia in 508 the second draw (sample 3) at a lower concentration than S. enterica, which may indicate a 509 secondary infection in this patient since S. maltophilia is an opportunistic pathogen. The patient

510 did not have antibiotic exposure at the time of either blood draw, so the decrease in *S. enterica* 511 may have resulted from the patient naturally beginning to clear the infection. This highlights the 512 possibility of using U-dHRM to track infections over time and in response to treatment.

512 513

514 *S. maltophilia* was also detected by U-dHRM and BCID in sample 4. *S. maltophilia* is an 515 emerging pathogen of concern for nosocomial infections. It is being isolated more frequently 516 and can be found ubiquitously in hospital environments.<sup>64,65</sup> The time saved by U-dHRM 517 detection of this organism (~7hr) could have resulted in faster treatment with appropriate 518 antimicrobial therapies, since this organism is inherently multidrug-resistant.<sup>66</sup>

519

520 In one case, sample 5, U-dHRM identified the causative pathogen while post-culture ePlex PCR 521 failed. This sample took over a day to grow out in culture and be identified, meaning that U-522 dHRM would have provided a faster detection and identification time.

523

524 In sample 7, U-dHRM returned low confidence calls, with one of them partially matched to the 525 causative pathogen, Klebsiella. Blood culture did not identify the causative pathogen in the matched sample. However, subsequent blood cultures did identify Klebsiella. Unfortunately, 526 527 matched U-dHRM samples for these subsequent cultures were not available. Low confidence 528 calls result from disagreement between the two ML classification methods used, which can arise 529 due to the organism not being in the database or due to melt curve noise, which can prevent 530 confident classification and identification. Expansion of the digital melt curve database with 531 more organisms and more training curves for each organism is expected to improve curve 532 calling confidence.

533 534

# 535 CONCLUSIONS

536 Overall, the U-dHRM approach demonstrated 100% concordance with blood culture (positive/ 537 negative) and 90.5% concordance with clinician adjudicated blood culture results (positive 538 BSI/negative BSI). In all samples representing true bacteremia, U-dHRM correctly identified the 539 causative pathogen, achieving 100% concordance with the genus and species identified by 540 culture. U-dHRM has a much faster time to result than traditional blood culture methods, and 541 automation of the U-dHRM process is expected to further reduce the sample-to-answer time. 542 However, this pilot study of 21 patient samples needs to be further validated by testing a larger 543 cohort across multiple medical centers. Additional organisms will also need to be added to the 544 database to encompass all of the most clinically relevant organisms for sepsis. Further 545 optimization of our ML algorithm and additional training data is expected to improve the ability of 546 U-dHRM to call organisms with high confidence as well as to discern when samples contain 547 organisms that are not yet in the database.

548 549 **ETHICS** 

550 The clinical study protocol was reviewed and approved by the Institutional Review Board (IRB) 551 and Ethics Committee (No. 191392) of the University of California, San Diego (UCSD) and Rady 552 Children's Hospital (RCHSD). Consent was not required for the scavenging of remnant CBC 553 samples.

#### 554

558

### 555 DATA AVAILABILITY

556 The data that support the findings of this study, in accordance with IRB designated restrictions, 557 are available from the corresponding author upon request.

## 559 ACKNOWLEDGEMENTS

560 This work was supported by the National Institute of Allergy and Infectious Diseases of the 561 National Institutes of Health (award number R01Al134982), a Burroughs Wellcome Fund Career 562 Award at the Scientific Interface (award number 1012027 to S.I.F.), and UCSD CTRI, FISP, and 563 AIM pilot grants. We acknowledge and thank MelioLabs for the use of their MeltRead Platform 564 and for their assistance in data analysis with their ML pipeline.

565

566 S.I.F. and A.A. designed the study. A.A. conducted experiments and analyzed data with 567 assistance from T.G. N.R. provided clinical adjudication and general guidance in interpreting 568 S.M.L., K.M., and E.S. provided cord blood for analytical validation and clinical results. 569 database development and additional clinician guidance. A.K., A.S., and M.S. developed the 570 algorithm used for machine learning and used it to perform guantification and classification, and 571 assisted in interpretation of the machine learning results. D.P., P.K., K.L, and M.C. provided 572 clinical isolates and performed blood culture testing on samples acquired from the blood bank. 573 M.V., S.L, M.C, and Y.T. collected clinical samples and provided the associated clinical data 574 from Rady Children's Hospital.

### 576 **DISCLAIMER**

577 The views expressed in this article are those of the author(s) and do not necessarily reflect the 578 official policy or position of the Department of the Navy, Department of Defense, or the US 579 Government.

580

575

## 581 DISCLOSURE

582 S.I.F. is a scientific cofounder, director, and advisor of MelioLabs, Inc., and has an equity 583 interest in the company. S.M.L. is an advisor of Melio and has equity interest. M.S. is co-founder 584 and CEO of Melio and has equity interest. A.K. and A.S. are employees of Melio. NIAID award 585 number R01Al134982 has been identified for conflict of interest management based on the 586 overall scope of the project and its potential benefit to MelioLabs, Inc.; however, the research 587 findings included in this particular publication may not necessarily relate to the interests of 588 MelioLabs, Inc. The terms of this arrangement have been reviewed and approved by the 589 University of California, San Diego, in accordance with its conflict of interest policies.

590 591

## 592 **REFERENCES**

- 593 1. WHO. Global report on the epidemiology and burden of sepsis: current evidence,
- identifying gaps and future directions. Preprint at (2020).
- 595 2. Seymour, C. W. et al. Time to Treatment and Mortality during Mandated Emergency Care

- 596 for Sepsis. *N. Engl. J. Med.* **376**, 2235–2244 (2017).
- Biondi, E. A. *et al.* Blood culture time to positivity in febrile infants with bacteremia. *JAMA Pediatr.* **168**, 844–849 (2014).
- 599 4. Mukhopadhyay, S. *et al.* Time to positivity of blood cultures in neonatal late-onset
- 600 bacteraemia. Arch. Dis. Child. Fetal Neonatal Ed. **107**, 583–588 (2022).
- 5. Eubank, T. A., Long, S. W. & Perez, K. K. Role of Rapid Diagnostics in Diagnosis and
- 602 Management of Patients With Sepsis. The Journal of Infectious Diseases vol. 222 S103-
- 603 S109 Preprint at https://doi.org/10.1093/infdis/jiaa263 (2020).
- 604 6. Schelonka, R. L. *et al.* Volume of blood required to detect common neonatal pathogens. *J.*605 *Pediatr.* **129**, 275–278 (1996).
- 606 7. Sinha, M. *et al.* Emerging Technologies for Molecular Diagnosis of Sepsis. *Clin. Microbiol.*607 *Rev.* **31**, (2018).
- 8. Stranieri, I. et al. Assessment and comparison of bacterial load levels determined by
- 609 quantitative amplifications in blood culture-positive and negative neonatal sepsis. *Rev. Inst.*
- 610 *Med. Trop. Sao Paulo* **60**, e61 (2018).
- 9. Lancaster, D. P., Friedman, D. F., Chiotos, K. & Sullivan, K. V. Blood Volume Required for
- 612 Detection of Low Levels and Ultralow Levels of Organisms Responsible for Neonatal
- Bacteremia by Use of Bactec Peds Plus/F, Plus Aerobic/F Medium, and the BD Bactec FX
- 614 System: an *In Vitro* Study. *Journal of Clinical Microbiology* vol. 53 3609–3613 Preprint at
- 615 https://doi.org/10.1128/jcm.01706-15 (2015).
- 616 10. Hall, K. K. & Lyman, J. A. Updated review of blood culture contamination. *Clin. Microbiol.*617 *Rev.* 19, 788–802 (2006).
- 618 11. Zhang, Y., Hu, A., Andini, N. & Yang, S. A 'culture' shift: Application of molecular
- 619 techniques for diagnosing polymicrobial infections. *Biotechnology Advances* vol. 37 476–
- 620 490 Preprint at https://doi.org/10.1016/j.biotechadv.2019.02.013 (2019).
- 12. Venkatesh, M., Flores, A., Luna, R. A. & Versalovic, J. Molecular microbiological methods

- 622 in the diagnosis of neonatal sepsis. Expert Review of Anti-infective Therapy vol. 8 1037–
- 623 1048 Preprint at https://doi.org/10.1586/eri.10.89 (2010).
- 13. Kralik, P. & Ricchi, M. A Basic Guide to Real Time PCR in Microbial Diagnostics:
- 625 Definitions, Parameters, and Everything. *Front. Microbiol.* **8**, 108 (2017).
- 626 14. Yang, S. & Rothman, R. E. PCR-based diagnostics for infectious diseases: uses,
- 627 limitations, and future applications in acute-care settings. Lancet Infect. Dis. 4, 337–348
- 628 (2004).
- 629 15. Øvstebø, R. et al. Use of robotized DNA isolation and real-time PCR to quantify and identify
- 630 close correlation between levels of Neisseria meningitidis DNA and lipopolysaccharides in
- 631 plasma and cerebrospinal fluid from patients with systemic meningococcal disease. J. Clin.
- 632 *Microbiol.* **42**, 2980–2987 (2004).
- 633 16. Hajia, M. et al. Limitations of Different PCR Protocols Used in Diagnostic Laboratories: A
- 634 Short Review. *Modern Medical Laboratory Journal* vol. 1 1–6 Preprint at
- 635 https://doi.org/10.30699/mmlj17-01-01 (2018).
- 17. Taylor, S. C. et al. The Ultimate qPCR Experiment: Producing Publication Quality,
- 637 Reproducible Data the First Time. *Trends Biotechnol.* **37**, 761–774 (2019).
- 18. Klein, D. Quantification using real-time PCR technology: applications and limitations.
- 639 *Trends in Molecular Medicine* vol. 8 257–260 Preprint at https://doi.org/10.1016/s1471-
- 640 4914(02)02355-9 (2002).
- 19. Handschur, M., Karlic, H., Hertel, C., Pfeilstöcker, M. & Haslberger, A. G. Preanalytic
- 642 removal of human DNA eliminates false signals in general 16S rDNA PCR monitoring of
- bacterial pathogens in blood. *Comp. Immunol. Microbiol. Infect. Dis.* **32**, 207–219 (2009).
- 644 20. Rivas, R., Velázquez, E., Zurdo-Piñeiro, J. L., Mateos, P. F. & Martínez Molina, E.
- 645 Identification of microorganisms by PCR amplification and sequencing of a universal
- 646 amplified ribosomal region present in both prokaryotes and eukaryotes. J. Microbiol.
- 647 *Methods* **56**, 413–426 (2004).

- 648 21. Sachse, K. Specificity and Performance of PCR Detection Assays for Microbial Pathogens.
- 649 *Molecular Biotechnology* vol. 26 61–80 Preprint at https://doi.org/10.1385/mb:26:1:61
  650 (2004).
- 22. Hoffmeister, M. & Martin, W. Interspecific evolution: microbial symbiosis, endosymbiosis
- and gene transfer. *Environ. Microbiol.* **5**, 641–649 (2003).
- 653 23. O'Brien, T. W. et al. Mammalian mitochondrial ribosomal proteins (2). Amino acid
- sequencing, characterization, and identification of corresponding gene sequences. *J. Biol. Chem.* 274, 36043–36051 (1999).
- 656 24. Schwartz, R. M. & Dayhoff, M. O. Origins of Prokaryotes, Eukaryotes, Mitochondria, and
- 657 Chloroplasts. *Science* vol. 199 395–403 Preprint at https://doi.org/10.1126/science.202030
  658 (1978).
- Eperon, I. C., Anderson, S. & Nierlich, D. P. Distinctive sequence of human mitochondrial
  ribosomal RNA genes. *Nature* vol. 286 460–467 Preprint at
- 661 https://doi.org/10.1038/286460a0 (1980).
- 26. Millar, B. C., Xu, J. & Moore, J. E. Risk assessment models and contamination
- 663 management: implications for broad-range ribosomal DNA PCR as a diagnostic tool in 664 medical bacteriology. *J. Clin. Microbiol.* **40**, 1575–1580 (2002).
- 665 27. Niles, D. T., Wijetunge, D. S. S., Palazzi, D. L., Singh, I. R. & Revell, P. A. Plasma
- 666 Metagenomic Next-Generation Sequencing Assay for Identifying Pathogens: a
- 667 Retrospective Review of Test Utilization in a Large Children's Hospital. J. Clin. Microbiol.
- 668 **58**, (2020).
- 28. The Next Big Thing? Next-Generation Sequencing of Microbial Cell-Free DNA Using the
  Karius Test. *Clin. Microbiol. Newsl.* 43, 69–79 (2021).
- 29. Hu, B. et al. A Comparison of Blood Pathogen Detection Among Droplet Digital PCR,
- 672 Metagenomic Next-Generation Sequencing, and Blood Culture in Critically III Patients With
- 673 Suspected Bloodstream Infections. *Front. Microbiol.* **12**, 641202 (2021).

- 30. Hogan, C. A. *et al.* Clinical Impact of Metagenomic Next-Generation Sequencing of Plasma
- 675 Cell-Free DNA for the Diagnosis of Infectious Diseases: A Multicenter Retrospective Cohort

676 Study. Clin. Infect. Dis. **72**, 239–245 (2021).

- 31. Babady, N. E. Clinical Metagenomics for Bloodstream Infections: Is the Juice Worth the
  Squeeze? *Clin. Infect. Dis.* **72**, 246–248 (2020).
- 32. Niles, D. T., Lee, R. A., Lamb, G. S., Dhaheri, F. A. & Boguniewicz, J. Plasma cell-free
- 680 metagenomic next generation sequencing in the clinical setting for the diagnosis of
- 681 infectious diseases: a systematic review and meta-analysis. *Diagn. Microbiol. Infect. Dis.*
- 682 **105**, 115838 (2023).
- 683 33. Miller, S. & Chiu, C. The Role of Metagenomics and Next-Generation Sequencing in

684 Infectious Disease Diagnosis. *Clin. Chem.* **68**, 115–124 (2021).

- 34. Wang, H. *et al.* Clinical diagnostic application of metagenomic next-generation sequencing
  in children with severe nonresponding pneumonia. *PLoS One* **15**, e0232610 (2020).
- 35. Benamu, E. et al. Plasma Microbial Cell-free DNA Next-generation Sequencing in the
- Diagnosis and Management of Febrile Neutropenia. *Clin. Infect. Dis.* 74, 1659–1668
  (2021).
- 690 36. Church, D. L. *et al.* Performance and Application of 16S rRNA Gene Cycle Sequencing for
  691 Routine Identification of Bacteria in the Clinical Microbiology Laboratory. *Clin. Microbiol.*692 *Rev.* 33, (2020).
- 693 37. Dunne, W. M., Westblade, L. F. & Ford, B. Next-generation and whole-genome sequencing
  694 in the diagnostic clinical microbiology laboratory. *Eur. J. Clin. Microbiol. Infect. Dis.* 31,
- 695 1719–1726 (2012).
- 38. Deurenberg, R. H. *et al.* Reprint of 'Application of next generation sequencing in clinical
  microbiology and infection prevention'. *J. Biotechnol.* **250**, 2–10 (2017).
- 39. Bertelli, C. & Greub, G. Rapid bacterial genome sequencing: methods and applications in
- 699 clinical microbiology. *Clin. Microbiol. Infect.* **19**, 803–813 (2013).

	700	40. B	oers, S.	A., Jansen	R. & H	lavs, J. F	P. Understanding	and overcomi	ing the pitfalls an
--	-----	-------	----------	------------	--------	------------	------------------	--------------	---------------------

- 501 biases of next-generation sequencing (NGS) methods for use in the routine clinical
- microbiological diagnostic laboratory. *Eur. J. Clin. Microbiol. Infect. Dis.* **38**, 1059–1070
- 703 (2019).
- 41. Velez, D. O. *et al.* Massively parallel digital high resolution melt for rapid and absolutely
  quantitative sequence profiling. *Sci. Rep.* **7**, 42326 (2017).
- 42. Sinha, M., Mack, H., Coleman, T. P. & Fraley, S. I. A High-Resolution Digital DNA Melting
  Platform for Robust Sequence Profiling and Enhanced Genotype Discrimination. *SLAS Technol* 23, 580–591 (2018).
- 43. Fraley, S. I. et al. Universal digital high-resolution melt: a novel approach to broad-based

710 profiling of heterogeneous biological samples. *Nucleic Acids Res.* 44, 508 (2016).

44. Fraley, S. I. et al. Nested Machine Learning Facilitates Increased Sequence Content for

T12 Large-Scale Automated High Resolution Melt Genotyping. Sci. Rep. 6, 19218 (2016).

713 45. Langouche, L. et al. Data-driven noise modeling of digital DNA melting analysis enables

prediction of sequence discriminating power. *Bioinformatics* **36**, 5337–5343 (2021).

46. Sinha, M., Mack, H., Coleman, T. P. & Fraley, S. I. A High-Resolution Digital DNA Melting

- 716 Platform for Robust Sequence Profiling and Enhanced Genotype Discrimination. *SLAS*
- 717 *Technol* **23**, 580–591 (2018).
- 718 47. Aralar, A. et al. Improving Quantitative Power in Digital PCR through Digital High-
- 719 Resolution Melting. J. Clin. Microbiol. 58, (2020).

48. Soejima, T., Schlitt-Dittrich, F. & Yoshida, S.-I. Polymerase chain reaction amplification

- 721 length-dependent ethidium monoazide suppression power for heat-killed cells of
- 722 Enterobacteriaceae. *Anal. Biochem.* **418**, 37–43 (2011).
- Fittipaldi, M., Nocker, A. & Codony, F. Progress in understanding preferential detection of
  live cells using viability dyes in combination with DNA amplification. *J. Microbiol. Methods*
- 725 **91**, 276–289 (2012).

- 50. Baymiev, A. K. et al. Modern Approaches to Differentiation of Live and Dead Bacteria Using
- 727 Selective Amplification of Nucleic Acids. *Microbiology* vol. 89 13–27 Preprint at
- 728 https://doi.org/10.1134/s0026261720010038 (2020).
- 51. Chakravorty, S., Helb, D., Burday, M., Connell, N. & Alland, D. A detailed analysis of 16S
- ribosomal RNA gene segments for the diagnosis of pathogenic bacteria. *Journal of*
- 731 Microbiological Methods vol. 69 330–339 Preprint at
- 732 https://doi.org/10.1016/j.mimet.2007.02.005 (2007).
- 52. Cruz, A. T. et al. Updates on pediatric sepsis. J Am Coll Emerg Physicians Open 1, 981-
- 734 993 (2020).
- 53. Aralar, A. et al. Improving Quantitative Power in Digital PCR through Digital High-
- 736 Resolution Melting. J. Clin. Microbiol. 58, (2020).
- 54. Hasan, M. R. et al. Depletion of Human DNA in Spiked Clinical Specimens for Improvement
- of Sensitivity of Pathogen Detection by Next-Generation Sequencing. J. Clin. Microbiol. 54,
- 739 919–927 (2016).
- 55. Aralar, A. et al. Improving Quantitative Power in Digital PCR through Digital High-
- 741 Resolution Melting. J. Clin. Microbiol. 58, (2020).
- 56. Brunskill, S. *et al.* What is the maximum time that a unit of red blood cells can be safely left
- out of controlled temperature storage? *Transfus. Med. Rev.* **26**, 209–223.e3 (2012).
- 57. United Kingdom Blood Services. *Handbook of Transfusion Medicine*. (Stationery Office,
  2013).
- 58. Funes-Huacca, M. E., Opel, K., Thompson, R. & McCord, B. R. A comparison of the effects
- of PCR inhibition in quantitative PCR and forensic STR analysis. *Electrophoresis* 32, 1084–
  1089 (2011).
- 59. Ayrapetyan, M., Williams, T. & Oliver, J. D. Relationship between the Viable but
- 750 Nonculturable State and Antibiotic Persister Cells. J. Bacteriol. 200, (2018).
- 751 60. Marchant, E. A., Boyce, G. K., Sadarangani, M. & Lavoie, P. M. Neonatal sepsis due to

752 coagulase-negative staphylococci. *Clin. Dev. Immunol.* **2013**, 586076 (2013).

- 753 61. Wain, J. et al. Quantitation of bacteria in bone marrow from patients with typhoid fever:
- relationship between counts and clinical features. J. Clin. Microbiol. **39**, 1571–1576 (2001).
- 62. Mogasale, V., Ramani, E., Mogasale, V. V. & Park, J. What proportion of Salmonella Typhi
- cases are detected by blood culture? A systematic literature review. Ann. Clin. Microbiol.
- 757 *Antimicrob.* **15**, 32 (2016).
- 63. Massi, M. N. et al. Quantitative detection of Salmonella enterica serovar Typhi from blood
- of suspected typhoid fever patients by real-time PCR. *Int. J. Med. Microbiol.* **295**, 117–120
- 760 (2005).
- 64. Brooke, J. S. New strategies against Stenotrophomonas maltophilia: a serious worldwide
- intrinsically drug-resistant opportunistic pathogen. *Expert Rev. Anti. Infect. Ther.* 12, 1–4
  (2014).
- 65. Brooke, J. S. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. *Clin. Microbiol. Rev.* 25, 2–41 (2012).
- 766 66. Said, M. S., Tirthani, E. & Lesho, E. Stenotrophomonas Maltophilia. in StatPearls
- 767 (StatPearls Publishing, 2022).

768
769
770
771
772
773
774
775
776
777
778
779
780
781
782

783

20



791

**Predicted Class** 792 Figure 1. Digital melt curve database creation and algorithm training. Eleven organisms 793 were individually spiked into whole blood, processed with Molysis, and analyzed by U-dHRM 794 with V1F/V9R primers and IAC. A) Plot of representative digital melt curve signature for each 795 organism with the IAC curve region cropped out for visualization purposes. Raw organism 796 curves are shown in Supplementary Fig. 7. B) Confusion matrix showing digital melt curve 797 classification results for the machine learning algorithm. 798

799

800

801

802

803

804



805 806

Figure 2. Analytical validation of U-dHRM on spiked whole blood samples. A) Schematic
 showing the procedure for analytical validation studies comparing U-dHRM to quantitative blood
 culture. B) Plot comparing quantification of bacteria by U-dHRM versus culture. A 6-fold dilution

810 series of *E. coli* was prepared in PBS and spiked into whole blood. Controls included blank PBS

- spiked into blood and an extraction blank (EB, Molzyme SU buffer alone as input for Molysis
- 812 processing). It is assumed that one 16S copy/melt curve will be detected per CFU.
- 813



814

815 Figure 3. Pilot clinical testing on whole blood samples. A-I) Representative organism curves (red) that were matched with high confidence to database curves (black) by the machine 816 817 learning algorithm in each CBC sample. No curves were detected in CBC negatives. The 818 number of melt curves detected for each organism (cluster) is noted in the legends. J) Load of 819 individual clinically relevant organisms identified and guantified by U-dHRM in CBC samples. 820

821

#### 822 **TABLES**

823

#### 824 Table 1. Comparison of clinical diagnostics and U-dHRM results.

Na	Clinical	Cultured	ePlex BCID	Preliminary	Final	Clinician	U-dHRM	U-dHRM Confidence
NO.	IIR	Organism	Result	Diagnosis	Diagnosis	Adjudication	U	Levei
1	0d, 22hr, 44min	S. epidermidis (CoNS)	S. epidermidis (CoNS)	Acute UTI + Fever	<i>E. coli</i> UTI	Negative	CoNS	High
2	2d, 12hr, 54min	S. enterica Typhi	S. enterica Typhi	Acute febrile illness in child	S <i>. enterica</i> Typhi BSI	Positive S. enterica	S. enterica	High
3	3d, 0hrs, 45min	S. enterica Typhi	S. enterica Typhi	Salmonella BSI	S. <i>enterica</i> Typhi BSI	Positive <i>S. enterica</i>	S. enterica, S. maltophilia	High
4	0d, 13hr, 24min	S. maltophilia	S. maltophilia	BSI	S. maltophilia CLABSI	Positive S. maltophilia	S. maltophilia	High
5	1d, 12hr, 20min	Salmonella spp.	Negative	Salmonella BSI	S. enterica BSI	Positive <i>S. enterica</i>	S. enterica, S. aureus	High
6	0d, 16hr, 59min	GPR	Bacteroides	Cellulitis	Poly- microbial SSTI	Negative	CoNS	High
7	0d, 16hr, 36min	GNR	Enterobacter non cloacae	BSI	Klebsiella CLABSI	Positive <i>Klebsiella</i>	K. pneumoniae	Low

\*CoNS = Coagulase Negative *Staphylococci*; BSI = Bloodstream Infection; UTI = Urinary Tract Infection; CLABSI =

826 Central Line Associated BSI; SSTI = Skin and Soft Tissue Infection.

827

b

True Class



CoNS	91.0%	0.0%	0.0%	0.7%	0.0%	0.0%	8.1%	0.0%	0.0%	0.0%
EC	0.0%	96.0%	3.2%	0.0%	0.0%	0.0%	0.1%	0.0%	0.0%	0.7%
EF	0.0%	4.2%	95.0%	0.0%	0.0%	0.0%	0.1%	0.0%	0.0%	0.5%
GBS	0.4%	0.0%	0.2%	98.2%	0.8%	0.0%	0.0%	0.0%	0.0%	0.4%
KP	0.1%	0.2%	0.0%	0.4%	96.9%	0.1%	0.0%	1.6%	0.0%	0.7%
PA	0.2%	0.0%	0.0%	0.4%	0.0%	99.2%	0.0%	0.1%	0.0%	0.0%
SA	7.2%	0.0%	0.0%	0.0%	0.0%	0.0%	92.8%	0.0%	0.0%	0.0%
SE	0.0%	0.0%	0.0%	0.1%	0.5%	0.3%	0.0%	98.7%	0.3%	0.0%
SM	0.1%	0.0%	0.1%	0.1%	0.0%	0.0%	0.0%	2.2%	97.5%	0.0%
SP	0.3%	0.1%	0.0%	0.0%	0.1%	0.0%	0.2%	0.0%	0.0%	99.2%
	No	<sup>2</sup> C	4	S	12	90	SA	L.	CN	R
C	. joj.	$\mathbf{v}$	~	G~	X <sup>*</sup>	`	5	2	-5	5

**Predicted Class** 





